Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

In this episode of the Oncology Brothers podcast, we were joined by two international experts — Professor Gary Tse, a pathologist from the Chinese University of Hong Kong, and Dr. Carlos Barrios, a medical oncologist from Brazil — to unpack the evolving landscape of HER2 testing in breast cancer. What was once a binary positive or negative classification has now expanded to include HER2-low and HER2-ultra-low, opening the door to new treatment options for the majority of breast cancer patients.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

 

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Key topics discussed included:

• How HER2 classification has evolved from a binary result to a continuous spectrum including HER2-low and HER2-ultra-low, driven by the efficacy of antibody drug conjugates like T-DXd
• Pre-analytical challenges in metastatic settings including tumor heterogeneity
• The role of IHC, ISH, NGS, and liquid biopsy in HER2 assessment, and how each tool fits into clinical practice.
• The importance of multidisciplinary collaboration between pathologists and oncologists to ensure accurate interpretation and optimal treatment selection.

Join us for this expert discussion on one of the most clinically impactful topics in breast oncology today. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology!

#HER2, #BreastCancer, #BiomarkerTesting, #PrecisionOncology, #OncologyBrothers